Recombinant adenovirus (rAd) and recombinant adeno-associated virus (rAAV) are among
the most extensively used vectors in gene therapy studies to date. These two vectors share …

The unique life cycle of adeno-associated virus (AAV) and its ability to infect both
nondividing and dividing cells with persistent expression have made it an attractive vector …

The discovery of naturally occurring adeno-associated virus (AAV) isolates in different
animal species and the generation of engineered AAV strains using molecular genetics …

Adeno-associated virus (AAV) was first discovered as a contaminant of adenovirus stocks in
the 1960s. The development of recombinant AAV vectors (rAAV) was facilitated by early …

Recombinant adeno-associated viruses (rAAV) are promising gene transfer vectors that
produce long-term expression without toxicity. To investigate future approaches for in utero …

Recombinant adeno-associated virus (rAAV) is capable of directing long-term, high-level
transgene expression without destructive cell-mediated immune responses. However …

Adeno-associated virus (AAV) is a promising vector for human somatic gene therapy.
However, its broad host range is a disadvantage for in vivo gene therapy, because it does …

Cesium chloride (CsCl)-and iodixanol-based density gradients represent the core step in
most protocols for serotype-independent adeno-associated virus (AAV) purification …

Adeno-associated virus (AAV) is a human parvovirus that is currently receiving widespread
attention for its potential use as a gene therapy vector. Construction of the recombinant AAV …

Abstract Adeno-associated virus (AAV), a defective parvovirus, was discovered more than
30 years ago. Interest in this virus for human gene therapy applications focuses on its non …